osteoarthritis
Rheumatology · 2005–2014
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| paracetamol Relief of persistent pain associated with osteoarthritis. | Nov 2014 | Not recommended | input received |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients requiring an NSAID who are at increased risk of… | Jul 2013 | Not recommended | no section in document |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of developing… | Nov 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Nov 2012 | Not recommended | unclear |
| etoricoxib Symptomatic treatment of osteoarthritis. | Jul 2008 | Not recommended | no section in document |
| etoricoxib Symptomatic treatment of osteoarthritis. | Jul 2008 | Not recommended | no section in document |
| etoricoxib Symptomatic treatment of osteoarthritis | Jul 2007 | Recommended | no section in document |
| etoricoxib Symptomatic treatment of osteoarthritis. | Jul 2007 | Recommended | no section in document |
| glucosamine hydrochloride Symptomatic treatment of osteoarthritis, specifically for knee pain associated with osteoarthritis. | Jul 2006 | Not recommended | no section in document |
| glucosamine hydrochloride Symptomatic treatment of osteoarthritis, specifically knee osteoarthritis. | Jul 2006 | Not recommended | no section in document |
| lumiracoxib Symptomatic treatment of osteoarthritis. | Nov 2005 | Recommended with restriction | no section in document |
| lumiracoxib Symptomatic treatment of osteoarthritis. | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$251M in government benefit over 2024–25, across 16,551,516 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| Naproxen and esomeprazole | $84.5M |
| naproxen and esomeprazole | $84.5M |
| paracetamol | $82M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| celecoxibANACOXIB Celecoxib 100 mg capsule blister pack | 1999 | 49 |
| meloxicamAGILOCAM meloxicam 15 mg capsule blister pack | 2001 | 44 |
| piroxicamAPO-PIROXICAM piroxicam 10mg capsule blister pack | 1992 | 9 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.